Orphazyme A/S

Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.

Strategic Partners A/S is a biopharmaceutical company, which engages in the research and development of treatments for rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.

Orphazyme A/SCompany announcement No. 01/2022Inside information       Company Registration No. 32266355

Orphazyme updates 2021 financial outlook

Orphazyme A/SCompany announcement No. 27/2021Company Registration No. 32266355

Orphazyme announces changes to the Board of Directors

Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Orphazyme AS Sponsored ADR (ORPH) Rating Upgrade to Buy

BEST Inc - ADR

Wish

Which penny stocks are on your November watchlist? The post Hot Penny Stocks to Buy Right Now?

Hot Penny Stocks to Buy Right Now? 3 to Watch Next Week

Orphazyme A/SCompany announcement        No. 25/2021Company Registration No. 32266355

Orphazyme establishes a U.S. At-the-Market Offering Program with Cowen

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on Orphazyme A/S's (NASDAQ: ORPH) ("Orphazyme") encouraging regulatory update following its recently held Type A meeting with the U.S. Food and Drug Administration ("FDA") on arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-P

CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C

Orphazyme A/S (NASDAQ: ORPH) shares are moving higher after providing a regulatory update for arimoclomol in Niemann-Pick disease type C (NPC). The Company had a collaborative dialogue with the FDA during the Type A meeting to discuss the Complete Response Letter.

Orphazyme Stock Gains After FDA Update On Arimoclomol In Rare Neurodegenerative Disorder

The stock price of Orphazyme A/S (NASDAQ: ORPH) increased by over 20% pre-market today. This is why it happened.

ORPH Stock: Why The Price Surged Today

Orphazyme A/SCompany announcement        No. 24/2021Inside informationCompany Registration No. 32266355

Orphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in Niemann-Pick disease type C

Today, retail investors and traders appear willing to put some big money down on Orphazyme and ORPH stock as a potential short-squeeze play. The post ORPH Stock Alert: What's Going on With Red-Hot Orphazyme Today?

ORPH Stock Alert: What's Going on With Red-Hot Orphazyme Today?

Orphazyme A/SCompany announcement        No. 22/2021Company Registration No. 32266355

Orphazyme provides regulatory and financial updates

LOS ANGELES, Sept. 7, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ: ORPH) for violations of the federal securities laws.

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - September 7, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or traceable to Orphazyme's September 29, 2020 initial public offering (the "IPO" or "Offering"); and/or (2) between September 29, 2020 and June 18, 2021, inclusive, (the "Class Period") of the important September 7, 2021 lead plaintiff deadline in the securities class action.SO WHAT:...

ORPH Final Deadline Today: Rosen, Leading Trial Attorneys, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important September 7 Deadline in Securities Class Action - ORPH

Los Angeles, California--(Newsfile Corp. - September 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ: ORPH) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on September 29, 2020 (the "IPO"), or between September 29, 2020 and June 18, 2021, inclusive...

DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ: ORPH) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired (1) Orphazyme American depositary shares ("ADSs") pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducte

Final Deadline for Investors with Losses Exceeding $500K to Actively Participate in the Orphazyme A/S (ORPH) Class Action - Bronstein, Gewirtz & Grossman, LLC

New York, New York--(Newsfile Corp. - September 6, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or traceable to Orphazyme's September 29, 2020 initial public offering (the "IPO" or "Offering"); and/or (2) between September 29, 2020 and June 18, 2021, inclusive, (the "Class Period") of the important September 7, 2021 lead plaintiff deadline in the securities class action.SO...

ORPH Final Deadline Tomorrow: Rosen, Top Ranked Global Counsel, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important September 7 Deadline in Securities Class Action - ORPH

NEW YORK, Sept. 5, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH) and certain of its officers and directors.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Orphazyme A/S of Class Action Lawsuit and Upcoming Deadline - ORPH

LOS ANGELES--(BUSINESS WIRE)---- $ORPH #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)

Los Angeles, California--(Newsfile Corp. - September 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ: ORPH) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on September 29, 2020 (the "IPO"), or between September 29, 2020 and June 18, 2021, inclusive (the...

TUESDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - September 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ: ORPH) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on September 29, 2020 (the "IPO"), or between September 29, 2020 and June 18, 2021, inclusive (the...

TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Orphazyme A/S (ORPH) CEO Christophe Bourdon on Q2 2021 Results - Earnings Call Transcript

Orphazyme A/SCompany announcement No. 21/2021CVR No.: 32266355

Orphazyme reports business highlights and financial results in Interim Report First Half 2021

NEW YORK, Aug. 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or traceable to Orphazyme's September 29, 2020 initial public offering (the "IPO" or "Offering"); and/or (2) between September 29, 2020 and June 18, 2021, inclusive, (the "Class Period") of the important September 7, 2021 lead plaintiff deadline in the securities class action. SO WHAT: If you purchased Orphazyme securities pursuant and/or traceable to the IPO and/or Orphazyme securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ORPH

Orphazyme A/SInvestor news        No. 08/2021Company Registration No. 32266355

Orphazyme to host Interim Report First Half 2021 investor call on August 31, 2021

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme") published the results from a Phase 2/3 trial of arimoclomol, an investigational heat-shock protein amplifier, in Niemann-Pick disease type C (NPC) in the peer-reviewed Journal of Inherited Metabolic Disease (JI

News for Orphazyme A/S Stock (ORPH)